Amgen and UCB announce positive top-line tesults from phase 3 study evaluating romosozumab In men with osteoporosis
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced positive top-line results for romosozumab from the pivotal Phase 3 placeBo-contRolled study evaluatIng the efficacy anD safety of romosozumab in treatinG mEn with osteoporosis (BRIDGE).
Abbott's Absorb, the first fully dissolving heart stent, earns positive review by FDA advisory committee
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced that an independent panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 9 to 0, with one abstention, that the benefits of Abbott's Absorb fully bioresorbable drug eluting coronary stent outweigh the risks.
Pfizer celebrates a year of achievements in 2015 annual review
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has released its 2015 integrated annual review, an in-depth look into the company's financial, social and environmental performance. 2015 was marked by breakthrough scientific research, collaborations and partnerships.
FDA grants Roche's Cancer Immunotherapy Atezolizumab priority review for advanced bladder cancer
- Details
- Category: Roche
Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and granted Priority Review for atezolizumab (anti-PDL1; MPDL3280A) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC)
Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial
- Details
- Category: Novo Nordisk
Novo Nordisk has announced the top-line results from the LEADER trial, which investigated the cardiovascular safety of Victoza® (liraglutide) over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events.
Pfizer commences $5 billion accelerated share repurchase
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase $5 billion of Pfizer's common stock. This agreement is part of Pfizer's existing share repurchase authorization.
AstraZeneca's potential medicine for neuromyelitis optica receives FDA Orphan Drug Designation
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the investigational anti-CD19 monoclonal antibody, MEDI-551, for the treatment of patients with neuromyelitis optica (NMO) as well as neuromyelitis optica spectrum disorders (NMOSD).
More Pharma News ...
- Sanofi Pasteur and MSD announce intent to end joint vaccines operations in Europe
- GSK names winners of 2015 Discovery Fast Track Challenge
- Bristol-Myers Squibb and LabCentral team up in Cambridge, Massachusetts to support promising biotech startup companies
- Merck, Pfizer and Verastem announce combination trial of avelumab and VS-6063 in ovarian cancer
- Merck and the European Molecular Biology Laboratory announce drug discovery collaboration
- AstraZeneca enters licensing agreement with China Medical System Holdings for hypertension medicine
- Acalabrutinib recommended for orphan drug designation in Europe for three indications